SELLAS Life Sciences Group Inc. (NASDAQ: SLS) Starts Presentation at 12th Annual LD Micro Main Event
SELLAS Life Sciences (NASDAQ: SLS) is a late-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company’s lead product candidate, galinpepimut-S, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets a broad spectrum of hematologic cancers and solid tumor indications. Galinpepimut-S is poised to enter pivotal Phase 3 clinical trials, pending funding availability, in patients with AML and mesothelioma. For more information, visit the company’s website at www.seedolab.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and…